Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Liquidia Technologies, Inc.

Clinical trials sponsored by Liquidia Technologies, Inc., explained in plain language.

Liquidia Technologies, Inc. LQDA NASDAQ

Biopharmaceutical company developing inhaled therapies for pulmonary diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet recruiting 2 Not yet finished but already full! 1

New inhaled therapy aims to ease lung blood pressure

Disease control Ongoing

This study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…

Phase: PHASE3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:02 UTC